Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 12, 2026BMC GastroenterologyOpen Access

TACE, lenvatinib, and PD-1 inhibitors in unresectable advanced hepatocellular carcinoma: an exploratory retrospective cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

HZHongyi ZhaoBeijing Shijitan HospitalTLTingting LiBeijing Shijitan HospitalYZY B ZhangCapital Medical University

Discussion

Loading...

Member takes

Overview

Exploratory retrospective cohort study finds improved survival with combined therapy in advanced HCC, suggesting effective treatment options.

Key Points

  • This study aims to assess the effectiveness and safety of combining TACE, lenvatinib, and PD-1 inhibitors in treating unresectable advanced hepatocellular carcinoma.
  • Conducted a retrospective cohort study involving 209 patients with unresectable advanced HCC from June 2016 to December 2022.
  • Patients were divided into TACE + lenvatinib and TACE + lenvatinib + PD-1 inhibitor groups, and outcomes were compared.
  • Propensity score-based inverse probability of treatment weighting (IPTW) was used to adjust for baseline imbalances.
  • Median overall survival was 16.49 months for the TACE + len + PD-1 group and 13.37 months for TACE + len (HR = 0.591, 95% CI 0.417–0.836, P = 0.003).
  • Median progression-free survival was 10.02 months for TACE + len + PD-1 and 3.42 months for TACE + len (HR = 0.638, 95% CI 0.479–0.848, P = 0.002).
  • Grade ≥ 3 adverse events occurred in 18.58% for the TACE + len + PD-1 group and 14.58% for TACE + len (P = 0.440).

Cite This Study

Zhao et al. (2026) studied this question.

synapsesocial.com/papers/6a2ba31a8101cf8926f01e4ehttps://doi.org/10.1186/s12876-026-04985-1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models2018 · 270 citations
  2. 2The regulation of immune checkpoints by the hypoxic tumor microenvironment2021 · 46 citations
  3. 3A novel necroptosis-related lncRNA signature predicts the prognosis and immune microenvironment of hepatocellular carcinoma2022 · 5 citations
  4. 4Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis2022 · 35 citations
  5. 5REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset2019 · 231 citations